Genomadix Inc. and Mayo Clinic are collaborating to advance precision medicine in telestroke care, leveraging rapid CYP2C19 genotyping to improve treatment decisions. The know-how license agreement grants Genomadix access to Mayo Clinic's expertise in telestroke, aiming to broaden the application of the Genomadix Cube CYP2C19 System in remote healthcare settings.
Rapid CYP2C19 Genotyping for Personalized Treatment
The core of this collaboration is the Genomadix Cube, a PCR-based system capable of generating CYP2C19 genotype results in approximately one hour. This rapid turnaround is crucial for clinicians making personalized dual-antiplatelet therapy (DAPT) decisions for stroke and cardiology patients. The American Heart Association's June 2024 scientific statement underscores the importance of CYP2C19 genetic testing for oral P2Y12 inhibitor therapy, further highlighting the relevance of this technology.
Clinical Significance and Impact
"This agreement represents a significant benefit for both organizations," said Steve Edgett, CEO of Genomadix. "With the know-how and expertise of Mayo Clinic, Genomadix aims to deliver rapid CYP2C19 genotype results helping guide therapeutic decisions for more patients in more locations."
About the Genomadix Cube
The Genomadix Cube is a molecular diagnostic instrument designed for point-of-need precision medicine genotyping. Its portability, ease of use, and on-demand processing enable users to obtain time-critical results quickly. The Cube platform is also available as an open platform (CubeX) for designing and running custom qPCR tests for research and product development.
